PKMYT1 and osteosarcoma: The development of PKMYT1 inhibitors is ongoing, and structural analysis and computer-aided design have led to the identification of several novel inhibitors active in the submicromolar range52, thus providing a basis for targeting PKMT1 in multiple cancers, including osteosarcoma.